DERM
What one share of Journey Medical holds
Pharmaceutical Preparations
We are a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions.
Journey Medical’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.55 |
|---|---|
| Profit | −$0.23 |
| Cash and investments | $0.93 |
| Debt | $0.93 |
| Book value | $1.17 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $4.11 | $0.49 | — | $0.47 | — | — |
| 2021 | $6.20 | −$4.32 | — | −$0.21 | — | $3.72 |
| 2022 | $4.20 | −$1.69 | $1.14 | −$1.91 | — | $0.97 |
| 2023 | $4.34 | −$0.21 | $0.27 | $0.01 | — | $1.12 |
| 2024 | $2.75 | −$0.72 | $0.73 | −$1.18 | — | $0.98 |
| 2025 | $2.52 | −$0.47 | — | −$0.51 | — | $1.30 |